Faster Genomic Testing for Children With Cancer - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Faster Genomic Testing for Children With Cancer

  • By

  • Helen Bristow

  • November 4, 2026

  • 3 min

Share

Objective:

The article reports on Addenbrooke’s Hospital’s use of rapid whole-genome sequencing (WGS) for children suspected of having cancer and discusses how faster results could inform early treatment decisions.

Approach:
  • Study: Addenbrooke’s Hospital used rapid WGS in the diagnosis of all pediatric patients suspected of having cancer.
  • NHS rollout: NHS England is supporting the Pediatric Cancer Genomic Network of Excellence to roll out rapid WGS across England over the next two years. Testing is planned through NHS Genomic Medicine Service laboratories in Cambridge and Bristol.
Key Findings:
  • Rapid WGS reduced the mean diagnostic turnaround time from 42 days to 3 days.
  • The study lead reported changes including access to precision medicines, less invasive surgery, reduced need for chemotherapy, and, in some cases, diagnoses of conditions other than cancer.
  • The current NHS WGS service for people aged 0–25 suspected of having cancer has a mean end-to-end turnaround time of 42 days.
Interpretation:

The study lead said genomic results available sooner could inform initial treatment decisions, which are often made within days of biopsy. She said results can potentially direct patients toward targeted treatments, help avoid harmful treatments, or support clinical-trial eligibility.

Limitations:
  • The provided article context reports mean turnaround times and examples of changes in diagnosis or care, but does not give the study sample size or detailed methods.
  • The national rollout is planned over the next two years; the provided context does not report outcomes from that rollout.
Conclusion:

The network plans to roll out rapid WGS across England over the next two years and aims to incorporate DNA methylation analysis using 5-base sequencing. It also aims to address sample-transport logistics so results can inform early clinical decisions.

Sources:

Original Source(s)

Related Content